Auxly Cannabis Group Inc. (XLY:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Auxly said 2025 was “transformational,” delivering 24% net revenue growth and adjusted EBITDA up 64% to $42 million, generating over $38 million in operating cash flow before working-capital changes. The company also noted balance-sheet risk was materially reduced after amending/extending its BMO-led credit facility and settling amounts owing to Imperial Brands shortly after last year’s AGM. Management indicated the improved financial footing is intended to broaden capital allocation options going forward, supporting an upbeat outlook for the remainder of 2026.

Analysis

The real signal is not brand leadership; it is that Auxly is trying to convert a survival story into an equity story. Once the debt overhang is reduced, the multiple can expand only if the market believes free cash flow is durable after working capital, excise, and normalization of promotional spend. In Canadian cannabis, that usually takes 2-3 quarters of proof, not one optimistic AGM.

The competitive read-through is more interesting than the company-level print. A scaled value brand with consistent supply tends to win shelf allocation from provincial buyers and displace weaker, less reliable incumbents; that pressures slower growers like WEED/OGI/TLRY more than it helps the category. The premium line is also important: if Auxly can hold mix while defending entry price share, it can shift from a discount operator to a branded consumer packager with better gross margin resilience.

The contrarian risk is that investors may be over-extrapolating margin leverage from a period when balance-sheet cleanup and inventory absorption flatter cash generation. If the next quarter shows that operating cash flow is still sensitive to working-capital swings, or if volume growth comes at the cost of pricing, the rerating can unwind quickly. For IMBBY, the settlement is mostly a nuisance removed rather than a meaningful earnings event.

Key Decisions for Investors

• Long XLY.TO tactically on weakness for a 1-3 month trade; this is a balance-sheet de-risking story, but size small because liquidity and sector volatility remain high. Falsify if gross margin or operating cash flow deteriorate in the next quarterly update.
• Pair long XLY.TO vs short a Canadian cannabis basket proxy (HMMJ.TO if available, otherwise WEED/OGI) over the next 6-12 weeks to isolate execution from the sector’s multiple compression. Best risk/reward is if Auxly continues to gain shelf share while peers disappoint on EBITDA conversion.
• Do not chase IMBBY; the credit cleanup is incrementally positive but likely immaterial to earnings. Treat any strength there as a sellable pop unless a larger capital-return or strategic update follows.
• Set an alert for the next quarterly release: if cash flow from operations holds after working capital and net leverage falls again, the stock can rerate for 6-18 months; if not, this remains a trade, not an investment.